Radioiodine ablation of post-surgical thyroid remnants by recombinant human TSH (rhTSH) in patients with moderately severe and severe Graves' orbithopathy (GO) - Graves' orbithopathy and rhTSH

IVERSITA' DEGLI STUDI DI MESSINA0 个研究点开始时间: 2012年3月2日最近更新: 2013年11月18日

适应症

试验速览

暂无简介。

•1. Hyperthyroidism onset<6 months treated only with anti-thyroid drugs; 2. GO onset <6 months; 3. Thyroid surgery indication (thyroid volume >15 ml and/or nodular goiter and/or hyperthyroidism relapse during despite anti-thyroid drugs and/or poor compliance to the medical treatment); 4. Moderately severe and severe GO; 5. Clinically active GO (Clinical Activity Score >3/7
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Hyperthyroidism onset >6 months or previously treated by radioiodine or thyroidectomy; 2. GO onset >6 months; 3. Mild GO; 4. Previous GO treatment by glucocorticoids, orbital irradiation or decompressive surgery; 5. Urgent orbital decompressive surgery; 6. Histopathological evidence of thyroid malignancy; 7. Pregnancy or breast-feading

发起方

IVERSITA' DEGLI STUDI DI MESSINA